Sanofi expands its Hyderabad center to 4,500 employees, boosting R&D and innovation in India.

Scientists developed electronic "cyborg" pancreas cells to monitor and boost insulin production in lab-grown islets, advancing diabetes treatment.

A brain training game targeting attention and speed may cut dementia risk by 25% in adults over 65.

Gazyva showed strong results in treating primary membranous nephropathy, a kidney disease, potentially becoming the first approved therapy for it.

Nuclera and leadXpro partner to accelerate drug discovery for tough membrane proteins using AI, cell-free synthesis, and cryo-EM.

The EU approved a higher Wegovy dose for obesity, boosting weight loss in clinical trials.

Halozyme Therapeutics hit $1.4B in 2025 revenue, driven by soaring royalties from key drugs, with strong growth expected in 2026.

A phase 2b trial shows duvakitug, from Sanofi and Teva, offers lasting relief for ulcerative colitis and Crohn’s disease patients.

AbbVie beat earnings expectations in Q4 2025, raised 2026 guidance, and saw increased investor interest.

FDA accepted Roche’s drug combo for ESR1-mutated advanced breast cancer, with review due by Dec. 18, 2026.